New Drug Product: Gemtesa
This slideshow show drug information for Gemtesa. Click here for the complete Gemtesa monograph.
Overactive Bladder/Enuresis
Gemtesa Now Available for Overactive Bladder Treatment
Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist.
Myrbetriq Approved for Pediatric Neurogenic Detrusor Overactivity
Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more.
Hormone Therapy May Reduce Nocturia After Menopause
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
Adding Vibegron to BPH Meds Safe, Effective for Overactive Bladder
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
Botox Approved for Neurogenic Detrusor Overactivity in Pediatric Patients
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.
Factors Associated With Low Persistence, Adherence to OAB Medication
Researchers conducted meta-analyses to investigate the real rates of persistence and adherence to overactive bladder drug therapies and moderating factors.
Mirabegron Granted Priority Review for Neurogenic Detrusor Overactivity
The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.
Gemtesa Approved for Overactive Bladder Treatment
The approval was based on data from the pivotal phase 3 EMPOWUR study.
Anticholinergics Linked to Increased Dementia Risk
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
